Assessment of high intensity focused ultrasound for the treatment of prostate cancer

Acta Chirurgica Belgica

Volumn 109, Issue 5, 2009, Pages 581-586

  Obyn, C ^a   Mambourg, F ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

High intensity focused ultrasound; Prostate cancer; Ultrasound, treatment

Indexed keywords

EID: 73049099088     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2009.11680492     Document Type: Article

References (36)

1. HAN M., PARTIN A. W., POUND C. R., EPSTEIN J. I., WALSH P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am, 2001, 28 (3): 555-565.
2. HULL G. W., RABBANI F., ABBAS F., WHEELER T. M., KATTAN M. W., SCARDINO P. T. Cancer control with radical prostatectomy alone in 1, 000 consecutive patients. J Urol, 2002, 167 (2 Pt 1): 528-534.
3. NILSSON S., NORLEN B. J., WIDMARK A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol, 2004, 43 (4): 316-381.
4. ATAMAN P., ZURLO A., ARTIGNAN X. et al. Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. Eur J Cancer, 2004, 40 (11): 1674-1681.
5. ROBINSON J. W., MORITZ S., RUNG T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys, 2002, 54 (4): 1063-1068.
6. STANFORD J. L., PENG Z., HAMILTON A. S. et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA, 2000, 283 (3): 354-360.
7. MURAT F.-J., POISSONNIER L., PASTICIER G., GELET A. High-intensity focused ultrasound (HIFU) for prostate cancer. Cancer Control, 2007, 14 (3): 244-249.
8. SHAUSSY C., THUROFF S., BERGSDORF T. Das Lokalrezidiv des Prostatakarzinoms nach kurativer Therapie. Therapieoption HIFU (Ablatherm). Der Urologe, 2006, 45 (10): 1271-1275.
9. BEERLAGE H. P., THUROFF S., DEBRUYNE F. M., CHAUSSY C., de la ROSETTE J. J. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology, 1999, 54 (2): 273-277.
10. OBYN C., MAMBOURG F. Rapid assessment van enkele nieuwe behandelingen voor prostaatkanker en goedaardige prostaathypertrofie: High-Intensity Focused Ultrasound (HIFU) voor prostaatkanker. Photoselective Vaporization of the Prostate (PVP) en holmium laser voor goedaardige prostaathypertrofie. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2008.
11. MERGLEN A., SCHMIDLIN F., PIORETTA G. et al. Short-and long-term mortality with localized prostate cancer. Arch Intern Med, 2007, 167 (18): 1944-1950.
12. NICE. Interventional procedure overview of high intensity focused ultrasound for prostate cancer, 2004.
13. BLANA A. et al. Pirst Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer. Eur Urol, 2007.
14. LEE H. M., HONG J. H., CHOI H. Y. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis, 2006, 9 (4): 439-443.
15. POISSONNIER L., CHAPELON J.-Y., ROUVIERE O. et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol, 2007, 51 (2): 381-387.
16. GELET A., CHAPELON J. Y., POISSONNIER L. et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology, 2004, 63 (4): 625-629.
17. MURAT. Mid-term Results Demonstrate Salvage High-Intensity Focused Ultrasound (HIFU) as an Effective and Acceptably Morbid Salvage Treatment Option for Locally Radiorecurrent Prostate Cancer. Eur Urol, 2008.
18. MAMBOURG F., VAN den BRUEL A., DEVRIESE S. et al. Health Technology Assessment prostate-specific-antigen (PSA) voor prostaatkankerscreening. Brussels: Belgian Health Care Knowledge Centre (KCE), 2006.
19. EUROPEAN ASSOCIATION OF UROLOGY. Guidelines on prostate cancer. European association of Urology, 2008.
20. NICE. Prostate cancer: diagnosis and treatment Developed for NICE by the National Collaborating Centre for Cancer, 2008.
21. UCHIDA T., OHKUSA H., YAMASHITA H. et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol, 2006, 13 (3): 228-33.
22. SOMITE d'EVALUATION et de DIFFUSION des INNOVATIONS TECHNOLOGIQUES. High intensity focused ultrasound (HIFU) for the treatment of localised prostate cancer (Ablatherm (R) system) - systematic review, expert panel. Report: Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT), 2004.
23. THUROFF S., CHAUSSY C., VALLANCIEN G. et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol, 2003, 17 (8): 673-677.
24. SHAUSSY C., THUROFF S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep, 2003, 4 (3): 248-252.
25. BLANA A., ROGENHOFER S., GANZER R., WILD P. J., WIELAND W. F., WALTER B. Morbidity associated with repeated transrectal highintensity focused ultrasound treatment of localized prostate cancer. World J Urol, 2006, 24 (5): 585-590.
26. SHAUSSY C G., THUROFF S. High-intensive focused ultrasound in localized prostate cancer. J Endourol, 2000, 14 (3): 293-299.
27. SHAUSSY C., THUROFF S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol, 2000, 4 (3): 179-182.
28. THUROFF S., CHAUSSY C. High-intensity focused ultrasound: complications and adverse events. Mol Urol, 2000, 4 (3): 183-187, discussion 89.
29. SHAUSSY C., THUROFF S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol, 2001, 15 (4): 437-440, discussion 47-48.
30. ROACH M. 3rd, HANKS G., THAMES H. Jr. et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 2006, 65 (4): 965-974.
31. GELET A., CHAPELON J. Y., BOUVIER R. et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol, 1996, 29 (2): 174-183.
32. GELET A., CHAPELON J. Y., BOUVIER R., PANGAUD C., LASNE Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol, 1999, 161 (1): 156-162.
33. GELET A., CHAPELON J. Y., BOUVIER R. et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol, 2000, 14 (6): 519-528.
34. POISSONNIER L., GELET A., CHAPELON J.-Y. et al. [Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10 ng/ml]. Prog Urol, 2003, 13 (1): 60-72.
35. GELET A., POISSONNIER L., CHAPELON J.-Y. et al. Traitement par ultrasons focalisés du cancer localisé de la prostate: Résultats carcinologiques et pronostic sexuel. Andrologie,2003, 13 (3): 242-251.
36. BLANA A., WALTER B., ROGENHOFER S., WIELAND W. F. Highintensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology, 2004, 63 (2): 297-300.